Table 2 Correlations between clinicopathological features and Stathmin expression in all the included cases
Characteristics | All (N = 44) | Stathmin | Â | ||
|---|---|---|---|---|---|
| Â | Â | Negative (N = 19) | Focal weak +ve (N = 12) | Diffuse strong +ve (N = 13) | p-value |
| Â | No. (%) | No. (%) | No. (%) | No. (%) | Â |
Age (years) | |||||
 Mean ± SD | 56.84 ±7.93 | 51.31 ±6.30 | 62.33 ±6.56 | 59.84 ±6.16 | <0.001* |
 Median (Range) | 57 (39-72) | 50 (39-65) | 62.50 (52-72) | 60 (44-70) |  |
 ≤ 55 years | 18 (40.9%) | 15 (83.3%) | 2 (11.1%) | 1 (5.6%) | <0.001‡ |
 > 55 years | 26 (59.1%) | 4 (15.4%) | 10 (38.5%) | 12 (46.2%) |  |
Histopathology | |||||
 LMS | 22 (50%) | 0 (0%) | 10 (45.5%) | 12 (54.5%) | <0.001‡ |
 ESS | 22 (50%) | 19 (86.4%) | 2 (9.1%) | 1 (4.5%) |  |
Size | |||||
 <5 cm | 6 (13.6%) | 2 (33.3%) | 4 (66.7%) | 0 (0%) | 0.046‡ |
 >5 cm | 38 (86.4%) | 17 (44.7%) | 8 (21.1%) | 13 (34.2%) |  |
Grade | |||||
 Grade I | 9 (20.5%) | 4 (44.4%) | 5 (55.6%) | 0 (0%) | 0.015‡ |
 Grade II | 12 (27.3%) | 5 (41.7%) | 5 (41.7%) | 2 (16.7%) |  |
 Grade III | 23 (52.3%) | 10 (43.5%) | 2 (8.7%) | 11 (47.8%) |  |
Extrauterine extension | |||||
 Absent | 6 (13.6%) | 2 (33.3%) | 4 (66.7%) | 0 (0%) | 0.003‡ |
 Present | 9 (20.5%) | 4 (44.4%) | 5 (55.6%) | 0 (0%) |  |
 N/A | 29 (65.9%) | 13 (44.8%) | 3 (10.3%) | 13 (44.8%) |  |
LVSI | |||||
 Absent | 21 (47.7%) | 7 (33.3%) | 10 (47.6%) | 4 (19%) | 0.014‡ |
 Present | 23 (52.3%) | 12 (52.2%) | 2 (8.7%) | 9 (39.1%) |  |
Adnexal invasion | |||||
 Absent | 11 (25%) | 4 (36.4%) | 7 (63.6%) | 0 (0%) | 0.003‡ |
 Present | 33 (75%) | 15 (45.5%) | 5 (15.2%) | 13 (39.4%) |  |
Lymph node | |||||
 Negative | 16 (36.4%) | 6 (37.5%) | 10 (62.5%) | 0 (0%) | <0.001‡ |
 Positive | 28 (63.6%) | 13 (46.4%) | 2 (7.1%) | 13 (46.4%) |  |
FIGO Stage | |||||
 Stage I | 6 (13.6%) | 2 (33.3%) | 4 (66.7%) | 0 (0%) | 0.001‡ |
 Stage II | 10 (22.7%) | 4 (40%) | 6 (60%) | 0 (0%) |  |
 Stage III | 13 (29.5%) | 5 (38.5%) | 0 (0%) | 8 (61.5%) |  |
 Stage IV | 15 (34.1%) | 8 (53.3%) | 2 (13.3%) | 5 (33.3%) |  |
Transgelin | |||||
 Negative | 25 (56.8%) | 19 (76%) | 5 (20%) | 1 (4%) | <0.001‡ |
 Focal weak +ve | 6 (13.6%) | 0 (0%) | 6 (100%) | 0 (0%0 |  |
 Diffuse strong +ve | 13 (29.5%) | 0 (0%) | 1 (7.7%) | 12 (92.3%) |  |
BCOR | |||||
 Negative | 23 (52.3%) | 4 (17.4%) | 10 (43.5%) | 9 (39.1%) | 0.007‡ |
 Focal weak +ve | 7 (15.9%) | 5 (71.4%) | 0 (0%) | 2 (28.6%) |  |
 Diffuse strong +ve | 14 (31.8%) | 10 (71.4%) | 2 (14.3%) | 2 (14.3%) |  |
Cyclin-D1 | |||||
 Negative | 24 (54.5%) | 2 (8.3%) | 10 (41.7%) | 12 (50%) | <0.001‡ |
 Focal weak +ve | 5 (11.4%) | 5 (100%) | 0 (0%) | 0 (0%) |  |
 Diffuse strong +ve | 15 (34.1%) | 12 (80%) | 2 (13.3%) | 1 (6.7%) |  |